PubRank

Norah A Terrault

Author PubWeight™ 95.35‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010 8.33
2 Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006 4.90
3 Burden of liver disease in the United States: summary of a workshop. Hepatology 2002 4.00
4 An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014 3.04
5 Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005 2.63
6 Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006 2.62
7 Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. Cancer 2014 2.26
8 Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 2005 2.24
9 PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 2011 1.85
10 Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study. Liver Transpl 2011 1.59
11 Alcohol use and hepatitis C. Hepatology 2002 1.55
12 Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA). J Clin Microbiol 2004 1.55
13 Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C. Liver Transpl 2012 1.54
14 Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation 2003 1.54
15 Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus. Liver Transpl 2011 1.52
16 Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology 2009 1.35
17 Outcomes of donor evaluation in adult-to-adult living donor liver transplantation. Hepatology 2007 1.31
18 Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia. Hepatology 2010 1.28
19 A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology 2013 1.21
20 Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology 2012 1.20
21 Limitations of conventionally derived chronic liver disease mortality rates: Results of a comprehensive assessment. Hepatology 2008 1.17
22 Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. Am J Gastroenterol 2009 1.16
23 Hospitalization rates before and after adult-to-adult living donor or deceased donor liver transplantation. Ann Surg 2010 1.13
24 New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl 2004 1.11
25 The changing epidemiology and natural history of hepatitis C virus infection. Clin Liver Dis 2006 1.11
26 Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology 2011 1.09
27 Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol 2008 1.08
28 Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005 1.06
29 Treatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos in. Liver Transpl 2015 1.01
30 Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection. Clin Gastroenterol Hepatol 2008 1.00
31 Management of hepatitis B in liver transplant recipients. J Viral Hepat 2007 0.99
32 Characteristics and management of patients with chronic hepatitis B in an integrated care setting. Dig Dis Sci 2014 0.96
33 Management of posttransplant hepatitis C infection. Curr Opin Organ Transplant 2010 0.94
34 Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection. Gastroenterology 2013 0.92
35 Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy. Liver Transpl 2011 0.92
36 Sex and hepatitis C. Am J Gastroenterol 2005 0.92
37 Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma. Liver Transpl 2012 0.91
38 Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2005 0.91
39 The option of HBIG-free prophylaxis against recurrent HBV. J Hepatol 2012 0.90
40 Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report. J Med Case Rep 2009 0.90
41 Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transpl 2006 0.88
42 Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. Transplantation 2015 0.88
43 Progression of biopsy-measured liver fibrosis in untreated patients with hepatitis C infection: non-Markov multistate model analysis. PLoS One 2011 0.88
44 Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transpl 2012 0.88
45 Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity. J Hepatol 2006 0.87
46 Human immunodeficiency virus and liver transplantation: Hepatitis C is the last hurdle. Hepatology 2015 0.86
47 Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients. Liver Transpl 2015 0.86
48 The epidemiology and clinical characteristics of patients with newly diagnosed alcohol-related liver disease: results from population-based surveillance. J Clin Gastroenterol 2010 0.85
49 Complementary and alternative medicine use in chronic liver disease patients. J Clin Gastroenterol 2010 0.85
50 Hepatitis C genotype influences post-liver transplant outcomes. Transplantation 2015 0.85
51 Ending vertical transmission of hepatitis B: the third trimester intervention. Hepatology 2014 0.84
52 Donor Risk Index for African American liver transplant recipients with hepatitis C virus. Hepatology 2013 0.84
53 Hepatitis C direct antiviral drugs and hepatic decompensation in patients with advanced cirrhosis: culprit or innocent bystander? Dig Dis Sci 2015 0.83
54 Effects of ethnicity and socioeconomic status on survival and severity of fibrosis in liver transplant recipients with hepatitis C virus. Liver Transpl 2012 0.83
55 Monocyte activation by interferon α is associated with failure to achieve a sustained virologic response after treatment for hepatitis C virus infection. J Infect Dis 2013 0.82
56 Organ donors with positive viral serology or malignancy: risk of disease transmission by transplantation. Transplantation 2002 0.82
57 Solid organ transplants in HIV-infected patients. Curr HIV/AIDS Rep 2013 0.81
58 Restricting liver transplant recipients to younger donors does not increase the wait-list time or the dropout rate: the hepatitis C experience. Liver Transpl 2014 0.80
59 Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfection. Clin Infect Dis 2004 0.79
60 Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation. Liver Transpl 2004 0.79
61 Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection. Liver Transpl 2008 0.79
62 Non-Markov multistate modeling using time-varying covariates, with application to progression of liver fibrosis due to hepatitis C following liver transplant. Int J Biostat 2010 0.79
63 Older donors: mounting risks for the hepatitis C-infected liver transplant recipient? Liver Transpl 2009 0.79
64 Bone Mineral Density, Bone Turnover, and Systemic Inflammation in Non-cirrhotics with Chronic Hepatitis C. Dig Dis Sci 2015 0.78
65 Treatment of recurrent hepatitis C after liver transplantation. Clin Liver Dis 2005 0.78
66 Management of patients co-infected with HBV and HCV. Expert Rev Anti Infect Ther 2009 0.77
67 Sofosbuvir and ribavirin use in wait-listed patients with hepatitis C should be selective. Liver Int 2015 0.77
68 Management of hepatitis C-infected liver transplant recipients at large North American centres: changes in recent years. Clin Transplant 2006 0.77
69 Should HCV-related cirrhosis be a contraindication for retransplantation? Liver Transpl 2003 0.76
70 Antiviral therapy in patients with chronic hepatitis B and cirrhosis. Gastroenterol Clin North Am 2004 0.76
71 Perspectives on treating hepatitis C infection in the liver transplantation setting. Curr Opin Organ Transplant 2016 0.75
72 Kidney and liver transplantation in HIV-infected patients: case presentations and review. AIDS Patient Care STDS 2003 0.75
73 High Rate of Hospital Admissions Among Patients with Cirrhosis Seeking Care in US Emergency Departments. Dig Dis Sci 2015 0.75
74 Individualizing hepatitis B infection prophylaxis in liver transplant recipients. J Hepatol 2011 0.75
75 Chronic Hepatitis B. Curr Treat Options Gastroenterol 2004 0.75
76 Reply to Prediction of hepatocellular carcinoma: using a complex risk model or assisting for smoking cessation? Cancer 2014 0.75
77 Antiviral therapy in liver transplant recipients: is SVR the only endpoint that matters? J Hepatol 2007 0.75
78 Prevalence and Predictors of Patient-Reported Long-Term Mental and Physical Health After Donation in the Adult to Adult Living Donor Liver Transplantation Cohort Study (A2ALL). Transplantation 2017 0.75
79 Approach to the treatment-experienced patient with hepatitis C virus genotype 1 infection. Infect Dis Clin North Am 2012 0.75
80 Management of recurrent hepatitis C in liver transplant recipients. Infect Dis Clin North Am 2006 0.75
81 Understanding the natural history of chronic HBV and HCV infections. J Fam Pract 2010 0.75
82 Sustained and focused hepatitis B virus nucleocapsid-specific T-cell immunity in liver transplant recipients compared to individuals with chronic and self-limited hepatitis B virus infection. Liver Transpl 2008 0.75
83 Short Course of Postoperative Hepatitis B Immunoglobulin Plus Antivirals Prevents Reinfection of Liver Transplant Recipients. Transplantation 2017 0.75
84 Pretransplant severe hepatic encephalopathy, peritransplant sodium and post-liver transplantation morbidity and mortality. Liver Int 2011 0.75
85 Is recurrent hepatitis C worse with living donors? Curr Opin Organ Transplant 2009 0.75